Back to Journals » OncoTargets and Therapy » Volume 10

The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

Authors Lu J, Li H, Guo P, Shen R, Luo Y, Ge Q, Shi WF, Li Y, Zhu W

Received 15 August 2017

Accepted for publication 11 October 2017

Published 13 November 2017 Volume 2017:10 Pages 5429—5437

DOI https://doi.org/10.2147/OTT.S149197

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Junjun Lu,1,* He Li,2,* Peng Guo,1 Rui Shen,3 Yingbin Luo,1 Qiao Ge,4 Wenfei Shi,1 Yan Li,1 Weikang Zhu1

1Department of Tumor, Shanghai Municipal Hospital of Traditional Chinese Medicine, 2Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, 3Department of Function, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 4Department of Tumor, Ninghai Hospital of Traditional Chinese Medicine, Ningbo, Zhejiang, China

*These authors contributed equally to this work


Objective: To evaluate the effect of CYP2D6 *10 polymorphism (C 100C>T, rs1065852) on clinical outcomes of female Asian breast cancer patients with tamoxifen adjuvant treatment.
Methods: Meta-analysis of retrospective cohort studies published in July 2017 was performed. Fifteen studies with 1,794 Asian breast cancer patients were included, using strict eligibility requirements. Associations of disease-free survival (DFS), overall survival (OS) and recurrence rate after tamoxifen intake, with CYP2D6 *10 polymorphism were investigated through random effects models.
Results: CYP2D6 *10 polymorphism was found to have effect on DFS and recurrence rate in various comparison models, but not on overall survival in the female Asian breast cancer patients.
Conclusion: In conclusion, our meta-analysis suggests that significant association of *10/*10 (TT) genotype with poorer DFS and recurrence exists in female Asian breast cancer patients with tamoxifen 20 mg/day adjuvant treatment. In the future, large and well-designed studies are required to illustrate the interactions of CYP2D6 genetic variants, including *10 polymorphism and tamoxifen response on female breast cancer patients.

Keywords: CYP2D6 *10, polymorphism, breast cancer, Asia, tamoxifen adjuvant treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]